ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

Efficacy of Niraparib on PFS in Patients With Recurrent Ovarian Cancer

Douglas A. Levine, MD
Published Online:7:41 PM, Mon September 25, 2017

Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, and director, Division of Gynecologic Oncology, NYU Langone Medical Center, discusses the efficacy of niraparib (Zejula) on progression-free survival in patients with recurrent ovarian cancer with partial response to the last platinum-based chemotherapy.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.